2 Stocks Battered by C-Suite Shakeups

Both ARA and SPWH just lost their CFOs

Managing Editor
Mar 28, 2019 at 2:37 PM
facebook twitter linkedin

The Dow has traded on both sides of breakeven today, as investors monitor U.S.-China trade talks. Among the stocks making big moves today, dialysis services provider American Renal Associates Holdings (NYSE:ARA) and sporting goods retailer Sportsman's Warehouse Holdings Inc (NASDAQ:SPWH) are lower, while biotech Tricida Inc (NASDAQ:TCDA) is soaring. Below, we'll take a closer look at the shares of ARA, SPWH, and TCDA.

Accounting Woes, C-Suite Exit Buries ARA

In the cellar of the New York Stock Exchange (NYSE) today is American Renal stock, down 38.2% to trade at $6, and earlier falling to a record low of $5.80. The dialysis services provider announced it has to restate its financials for 2014-2018, while the company's CFO also resigned. Even prior to today's collapse, ARA had been carving out a channel of lower lows since its August highs near $24.

Although the stock landed on the short-sale restricted (SSR) list today, several short sellers are likely cheering. More than 12% of ARA's total available float is sold short, accounting for a whopping 27 times the equity's average daily trading volume. 

SPWH Hit With Double-Dose of Ugly Headlines

Sportsman's Warehouse reported a fourth-quarter sales miss, while full-year guidance also fell short of estimates. To make matters worse, the company's CFO announced his resignation. All of this has SPWH down 12% to trade at $4.78, on track for its worst single-session drop since March 2018. The shares nabbed an annual high of $6.69 as recently as Feb. 27, but this month so far have shed 25% and are heading toward their fifth straight weekly loss.

A shift in analyst sentiment could keep the pressure on SPWH. Exactly 80% of brokerages covering the security rate it a "buy" or better, with zero "sells" on the books. Plus, its consensus 12-month price target of $6.90 is a roughly 45% premium to its current perch.

Upbeat Drug Data Powering TCDA's Best Day Ever

Tricida stock is up 45.9% to trade at $35.12, one of the best stocks on the Nasdaq today, after the drugmaker's kidney disease treatment met its main and secondary goals in long-term trials. A marketing application is expected to be submitted in the latter half of 2019.

TCDA is on track for its best day ever by a wide margin, but remains off its Sept. 10 record high of $40.10. The shares have nearly doubled since bottoming at $19.43 on Jan. 30, an area that coincides with the TCDA's June initial public offering (IPO) price of $19.  


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners